Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nadolol · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Nadolol (1 x 80 mg) Tablets (Invamed, Inc) |
| 2 | ACTIVE_COMPARATOR | Corgard (1 x 80 mg) Tablets (Bristol Laboratories) |
| Name | Type | Description |
|---|---|---|
| Nadolol (1 x 80 mg) Tablets (Invamed, Inc) | DRUG | - |
| Corgard (1 x 80 mg) Tablets (Bristol Laboratories) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Nadolol is a small molecule being studied for the treatment of high blood pressure. It is also being investigated for use in migraine headaches and chest pain. The drug is currently in Phase 1 clinical development and is being developed by Novartis AG.
Nadolol is being developed by Novartis AG, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 1 clinical development for the treatment of high blood pressure.
Nadolol is in Phase 1 clinical development. It is an investigational drug being studied for high blood pressure, and it has not been approved by the FDA. The drug is still in the early stages of clinical testing.
Nadolol has one completed clinical trial registered under the identifier NCT00960245. This Phase 1 study evaluated the relative bioavailability of Nadolol 80 mg tablets under fasting conditions in 34 healthy male volunteers.
Nadolol is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of high blood pressure. The drug is being studied in clinical trials but has not yet received regulatory approval.